Abstract
Objective: To examine the association between hormone replacement therapy (HRT) use and breast cancer incidence and to determine whether the association differs according to type of regimen. Method: Data were collected in Ontario from 404 incident cases and 403 age frequency-matched controls, between 1995 and 1996, using a self-administered questionnaire. Results: Multivariate analyses revealed an elevated odds ratio among long-term (≥ten years) HRT users (odds ratio (OR) = 1.80, 95% confidence interval (CI) 1.06–3.06). Risk among long-term estrogen–progestin users was substantially higher (OR = 3.48, 95% CI 1.00–12.11) than risk among long-term users of estrogen alone (OR = 1.74, 95% CI 0.93–3.24). Among both estrogen and estrogen–progestin users, positive associations were not observed for durations of use less than ten years. Conclusion: These data suggest that long-term use of HRT increases the risk of breast cancer and that estrogen–progestin therapy may be more detrimental than estrogen use alone.
Similar content being viewed by others
References
Barrett-Connor E, Stuenkel CA (2001) Hormone replacement therapy (HRT)-risks and benefits. Int J Epidemiol 30: 423-426.
Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276: 1389-1396.
Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19: 55-72.
Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E (1999) Postmenopausal estrogen replacement therapy and risk of Alzheimer's disease: a population-based study. Neurology 52: 965-970.
Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106: 574-582.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047-1059.
Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl cancer Inst 92: 328-332.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491.
Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281: 2091-2097.
Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.
Anderson E, Clarke RB, Howell A (1998) Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 3: 23-35.
Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestrogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35.
Lacroix AZ, Burke W (1997) Breast cancer and hormone replacement therapy. Lancet 350: 1042-1043.
Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565.
Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85: 6-10.
Smith DC, Prentice R, Thompson DJ, Herrmann WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167.
Ziel HK, Hinkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167-1170.
Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10: 253-260.
Percy C, Van Holten V (1990) International Classification of Diseases for Oncology, 2nd edn. Geneva: World Health Organization.
Slupik RI, Allison KC (1997) American Medical Association Complete Guide to Women's Health.
Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.
Persson I, Thurfjell E, Bergstrom R, Holmberg L (1997) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72: 758-761.
Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.
Colditz GA, Stampfer MJ, Willett WC, et al. (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 3: 433-439.
Colditz GA, Rosner B for the Nurses' Health Study Research Group (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 147(Suppl): 64S. Estrogen and estrogen-progestin replacement and breast cancer 589
Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S (1991) Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 134: 1386-1395.
Newcomb PA, Titus-Ernstoff L, Egan KM, et al. (2000) Estrogenprogestin use in relation to risk of lobular and ductal breast cancer. (1998). Am J Epidemiol 151: S64 (abstract).
Pike MC, Ross RK, Spicer DV (1998) Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 147: 718-721.
Siddle N, Sarrel P, Whitehead M (1987) The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 51: 604-608.
Kreiger N, Sloan M, Cotterchio M, Kirsh V (1999) The risk of breast cancer following reproductive surgery. Eur J Cancer 35: 97-101.
Laya MB, Larson EB, Taplin SH, White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88: 643-649.
Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7: 1133-1144.
Cauley JA, Lucas FL, Kuller LH, Bogt MT, Browner WS, Cummings SR for the Osteoporotic Fractures Research Group (1996) Bone mineral density and risk of breast cancer in older women. JAMA 276: 611-617.
Erlik Y, Meldrum DR, Judd HL (1982) Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 59: 403-407.
Longcope C, Crawford S, McKinlay S (1996) Endogenous estrogens: relationship between estrone, estradiol, non-protein bound estradiol, and hot flashes and lipids. Menopause 3: 77-84.
Johannes CB, Crawford SL, Posner JG, McKinlay SM (1994) Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 140: 439-452.
Bauer DC, Browner WS, Cauley JA, et al. (1993) Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 118: 657-665.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirsh, V., Kreiger, N. Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 13, 583–590 (2002). https://doi.org/10.1023/A:1016330024268
Issue Date:
DOI: https://doi.org/10.1023/A:1016330024268